Plain-English fact sheet
CJC-1295
Also known as CJC-1295 DAC, CJC-1295 without DAC
CJC-1295 is not FDA approved, has limited human clinical data, and appears on an FDA page describing potential significant safety risks in compounding.
Quick answer
CJC-1295 is an experimental growth-hormone-pathway peptide, not an FDA-approved medicine. Online names may refer to different molecules or formulations, making claims especially hard to interpret.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is CJC-1295?
CJC-1295 is a synthetic analog designed to extend growth hormone-releasing hormone signaling.
The term is used inconsistently online, including products described as with or without a drug-affinity complex (DAC). Evidence about one form should not be silently transferred to another.
Why are people interested in it?
It is promoted online for body composition, recovery, sleep, or anti-aging.
Those promotional claims extend well beyond the small human research base.
Current regulatory status
CJC-1295 is not FDA approved. FDA has identified limited clinical data and potential safety risks related to compounded products containing CJC-1295.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Growth-hormone-pathway effects in early studies
Evidence snapshot
Small early human studies examined hormone levels and tolerability. They do not establish broad clinical benefits for popular consumer goals.
Potential benefits being researched
- Early studies observed changes in growth hormone and IGF-1 measures.
- Changes in a laboratory marker are not proof of improved recovery, muscle growth, sleep, or longevity.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- FDA cites risks including immune reactions, peptide impurities, increased heart rate, and systemic vasodilatory reactions.
- Human safety data are limited, especially for long-term or repeated use.
- Unapproved products can add purity, strength, sterility, and labeling risks.
What we still do not know
- Long-term human safety
- Whether biomarker changes lead to meaningful health outcomes
- How product variants differ in exposure and risk
- Interactions and risks in people with common chronic conditions
Plain-English takeaway
CJC-1295 has a biological rationale and limited early human data, but no FDA-approved use and no strong evidence for the broad benefits commonly advertised online.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- 2ClinicalTrials.gov studies: CJC-1295
Current and completed registered clinical studies.
- 3PubMed research: CJC-1295
Peer-reviewed literature indexed by the National Library of Medicine.